No Data
No Data
Cansinobio (06185.HK) plans to hold a board of directors meeting on October 29 to approve third-quarter performance.
On October 16, Gelonghui reported that cansinobio (06185.HK) announced that the board of directors meeting will be held on October 29, 2024 (Tuesday), to consider and approve the third quarter performance of the company and its subsidiaries for the nine months ending September 30, 2024, as well as its release.
CANSINOBIO: NOTICE OF BOARD MEETING
[Hong Kong Stock Connect] Cansinobio (06185) rose more than 3% as it was approved by the Indonesian Food and Drug Administration for clinical trials of recombining poliomyelitis vaccines.
Golden Finance News | cansinobio (06185) stock price rose repeatedly, as of the time of publication, up 3.07%, at 26.9 Hong Kong dollars, with a turnover of 59.0767 million Hong Kong dollars. The company recently announced that it has obtained approval for Phase I/II clinical trials of the recombinant polio vaccine ("CS-2036") developed by the company from the Food and Drug Administration of India, enabling the initiation of relevant clinical trials. The CS-2036 candidate vaccine is based on the company's protein structure design and the development of virus-like particle ("VLP") assembly technology, and is a non-infectious VLP polio vaccine, in the live
CanSino Biologics to Obtain Further $17 Million Grant From Bill & Melinda Gates Foundation for Polio Vaccine
Cansinobio (06185) signed an agreement for the restructuring of polio vaccine and related combination vaccine projects.
Cansinobio (06185) announced that based on the recombinant polio vaccine (CS2036), a vaccine similar to...
Cansinobio recombinant poliomyelitis vaccine has obtained clinical trial approval in Indonesia.
Cansinobio announced that the company has obtained approval for phases I/II clinical trials from the Food and Drug Administration in India, allowing the initiation of relevant clinical trials for the developed recombinant poliovirus vaccine (CS-2036).
No Data
No Data